BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32885759)

  • 1. Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours.
    Wang L; Zhang G; Qin L; Ye H; Wang Y; Long B; Jiao Z
    Recent Pat Anticancer Drug Discov; 2020; 15(3):200-211. PubMed ID: 32885759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR and anti-EGFR nanobodies: review and update.
    Sharifi J; Khirehgesh MR; Safari F; Akbari B
    J Drug Target; 2021 Apr; 29(4):387-402. PubMed ID: 33210573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody.
    Omidfar K; Amjad Zanjani FS; Hagh AG; Azizi MD; Rasouli SJ; Kashanian S
    Mol Biol Rep; 2013 Dec; 40(12):6737-45. PubMed ID: 24052234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity Risk Profile of Nanobodies.
    Ackaert C; Smiejkowska N; Xavier C; Sterckx YGJ; Denies S; Stijlemans B; Elkrim Y; Devoogdt N; Caveliers V; Lahoutte T; Muyldermans S; Breckpot K; Keyaerts M
    Front Immunol; 2021; 12():632687. PubMed ID: 33767701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimers.
    Nevoltris D; Lombard B; Dupuis E; Mathis G; Chames P; Baty D
    ACS Nano; 2015 Feb; 9(2):1388-99. PubMed ID: 25603171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanobody-siRNA Conjugates for Targeted Delivery of siRNA to Cancer Cells.
    Zavoiura O; Brunner B; Casteels P; Zimmermann L; Ozog M; Boutton C; Helms MW; Wagenaar T; Adam V; Peterka J; Metz-Weidmann C; Deschaght P; Scheidler S; Jahn-Hofmann K
    Mol Pharm; 2021 Mar; 18(3):1048-1060. PubMed ID: 33444501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR).
    Zhu H; Zhao L; Li Z; Wen B; Qiu C; Liu M; Xu Z; Hu S; Li H
    Protein Expr Purif; 2019 May; 157():57-62. PubMed ID: 30735705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotoxins and nanobody-based immunotoxins: review and update.
    Khirehgesh MR; Sharifi J; Safari F; Akbari B
    J Drug Target; 2021 Sep; 29(8):848-862. PubMed ID: 33615933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".
    Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K
    Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
    Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A camelid nanobody against EGFR was easily obtained through refolding of inclusion body expressed in Escherichia coli.
    Xu L; Song X; Jia L
    Biotechnol Appl Biochem; 2017 Nov; 64(6):895-901. PubMed ID: 28853185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanobodies and Cancer: Current Status and New Perspectives.
    Allegra A; Innao V; Gerace D; Vaddinelli D; Allegra AG; Musolino C
    Cancer Invest; 2018 Apr; 36(4):221-237. PubMed ID: 29658806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A guide to: generation and design of nanobodies.
    Muyldermans S
    FEBS J; 2021 Apr; 288(7):2084-2102. PubMed ID: 32780549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking EGFR Activation with Anti-EGF Nanobodies via Two Distinct Molecular Recognition Mechanisms.
    Guardiola S; Varese M; Sánchez-Navarro M; Vincke C; Teixidó M; García J; Muyldermans S; Giralt E
    Angew Chem Int Ed Engl; 2018 Oct; 57(42):13843-13847. PubMed ID: 30152597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics.
    Mitchell RA; Luwor RB; Burgess AW
    Exp Cell Res; 2018 Oct; 371(1):1-19. PubMed ID: 30098332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering an anti-granulocyte colony stimulating factor receptor nanobody for improved affinity.
    Bakherad H; Farahmand M; Setayesh N; Ebrahim-Habibi A
    Life Sci; 2020 Sep; 257():118052. PubMed ID: 32634431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library.
    Yan J; Wang P; Zhu M; Li G; Romão E; Xiong S; Wan Y
    J Nanobiotechnology; 2015 May; 13():33. PubMed ID: 25944262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel anti-EGFR nanobody by phage display and its distinct paratope and epitope via homology modeling and molecular docking.
    Xi X; Sun W; Su H; Zhang X; Sun F
    Mol Immunol; 2020 Dec; 128():165-174. PubMed ID: 33130376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.
    Roovers RC; Laeremans T; Huang L; De Taeye S; Verkleij AJ; Revets H; de Haard HJ; van Bergen en Henegouwen PM
    Cancer Immunol Immunother; 2007 Mar; 56(3):303-317. PubMed ID: 16738850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.